Pharmidex to present at SCI event
September 30, 2014

Dr Mo Yaqoob from the Pharmidex team will be presenting on the topic 'How to avoid failure and achieve success in ADME/PK outsourcing'

Pharmidex To Present At SCI Event

Dr Mo Yaqoob will be representing Pharmidex with the presentation “How to avoid failure and achieve success in ADME/PK outsourcing.”


Dr Yaqoob’s presentation will begin at 14.30 pm. This event supported and organised by SCI (Science Meets Business) aims to demonstrate the developments between the outsourcing sector and the pharmaceutical industry over the last 20 years as well as the current challenges and best practice as seen from the supplier’s viewpoint.


The meeting will include speakers working in CROs from drug discovery through to development and will highlight what makes a successful collaboration, together with some potential pitfalls. Event details SCI, London, UK Tuesday 30 September 2014 14/15 Belgrave Square London SW1X 8PS.


For more info about this event and to register please go through the following link:


https://www.soci.org/Events/Display-Event.aspx?EventCode=FCHEM430

November 5, 2025
We’re excited to welcome Grace Horne as our new Bioanalytical Scientist! 🎉 Grace brings great enthusiasm and passion for science, and we’re confident she’ll make a fantastic contribution to our team. Welcome aboard, Grace, we’re thrilled to have you with us! 💜
November 4, 2025
We’re pleased to share that Janette Dalay Robertson , Business Development Manager at Pharmidex , will attend the DDW Turning Science into Business Symposium 2025 on Tuesday, 4th November, at the The Francis Crick Institute , London. Janette looks forward to connecting with industry leaders and exploring new collaboration opportunities.
November 3, 2025
We’re delighted to announce that Pharmidex will present our poster "Driving breakthroughs in Parkinson’s & neurodegeneration research” at the upcoming RSC BMCS meeting. With over 23 years of CNS expertise, we support biopharma partners in developing new therapies for Parkinson’s disease and tauopathies, through: 🔹 Parkinson’s & neurodegeneration models 🔹 Transgenic CNS lines (incl. 5xFAD) 🔹 Biomarker & BBB penetration studies Join us in Cambridge to explore how our GLP-accredited CNS platforms accelerate discovery and development.
More Posts